Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2009

View Archived Issues

Inovio Biomedical reports on preclinical studies of universal influenza vaccine

Sanofi-Aventis reports results from third quarter of 2009

TAK-901 has potent antitumor activity in xenograft mouse models of human malignancies

Roche initiates enrollment of cohort 2 in phase IIb trial of RG-7128 in HCV

AMG-900 exhibits potent activity against multidrug-resistant tumors in preclinical studies

Vical completes final patient follow-up visit of phase II TransVax trial in HCT recipients

Cytheris starts NCI/NIH-sponsored phase I/IIa trial of CYT-107 to enhance tumor vaccination

NIH awards grant to RPCI for study of tamoxifen in breast cancer

Clavis and Clovis sign development and commercialization agreement for CP-4126

FDA grants fast track designation to ARCA biopharma's Gencaro in heart failure

Galapagos initiates phase II clinical study of Nanocort for flares in MS

Addex reports preclinical data on ADX-48621 for Parkinson's disease

Novartis receives approval in Switzerland for Celtura pandemic influenza vaccine

Sinovac Biotech's Panflu.1 H1N1 vaccine approved for geriatric population in China

MenACWY-TT vaccine elicits a persistent immune response in adolescents

Non-adjuvanted H5N1 vaccine containing HA is safe and immunogenic in children

Millennium initiates phase I clinical trial of proteasome inhibitor MLN-9708

Ception Therapeutics and Cephalon provide results of phase IIb/III Cinquil trial

JUPITER data shows that rosuvastatin reduces risk of cardiovascular events

ADX-10059 is safe and effective in healthy subjects; evaluation in GERD anticipated

Shire submits MAA to EMEA for velaglucerase alfa for type 1 Gaucher disease

Palau Pharma discloses H4 receptor antagonists for the treatment of pain

Scancell to initiate a phase I/II trial of DNA ImmunoBody vaccine SCIB1 for melanoma

Gilead identifies SCD inhibitors for the treatment of diabetes

Caspase inhibitors disclosed by LG Life Sciences for acute hepatitis therapy

IRM and Novartis present ALK kinase inhibitors for cancer treatment

Novel 5-HT6 receptor antagonists disclosed by Solvay as anxiolytics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...